Characteristics of patients with F317L mutation, T315I mutation, other mutations, and no mutation
| Characteristic . | Mutation group . | ||||
|---|---|---|---|---|---|
| No mutation . | F317L . | T315I . | Other mutation . | P . | |
| Patients, n | 79 | 20* | 26 | 67 | |
| Age, y (range) | 50 (11-96) | 49 (34-66) | 52 (25-66) | 53 (22-80) | .51 |
| Prior therapy with interferon-α | 41 (52%) | 12 (60%) | 13 (50%) | 45 (67%) | .20 |
| CML stage at the start of imatinib | |||||
| Chronic | 62 (78%) | 12 (60%) | 20 (77%) | 55 (82%) | |
| Accelerated | 12 (15%) | 6 (30%) | 4 (15%) | 10 (15%) | |
| Blastic | 5 (7%) | 2 (10%) | 2 (8%) | 2 (3%) | .53 |
| Best response to imatinib | |||||
| CHR | 33 (41%) | 11 (55%) | 19 (70%) | 31 (46%) | |
| MCyR | 33 (41%) | 7 (35%) | 6 (23%) | 28 (41%) | |
| CCyR | 24 (30%) | 5 (25%) | 5 (19%) | 19 (28%) | .34 |
| Response duration, mo (range) | 25 (2-63) | 23 (2-69) | 20 (1-60) | 35 (2-70) | .048 |
| CML stage at imatinib failure | |||||
| Chronic | 28 (35%) | 8 (40%) | 9 (35%) | 23 (34%) | |
| Accelerated | 29 (37%) | 6 (30%) | 9 (35%) | 34 (51%) | |
| Blastic | 22 (28%) | 6 (30%) | 8 (30%) | 10 (15%) | |
| Myeloid | 15 (68%) | 4 (67%) | 4 (50%) | 6 (60%) | |
| Lymphoid | 7 (32%) | 2 (33%) | 4 (50%) | 4 (40%) | .37 |
| Clonal evolution | 37 (47%) | 8 (40%) | 9 (35%) | 23 (34%) | .19 |
| Transformation to accelerated or blastic phase | 40 (51%) | 6 (30%) | 14 (54%) | 38 (57%) | .20 |
| No. treated with 2nd TKI | 73 | 9 | 14 | 65 | |
| Response to subsequent TKI | |||||
| Hematologic | 61 (84%) | 7 (78%) | 5 (36%) | 53 (82%) | |
| Cytogenetic | 31 (42%) | 3 (33%) | 0 (0%) | 31 (48%) | .003 |
| No. dead | 31 (39%) | 8 (40%) | 11 (42%) | 25 (37%) | .99 |
| Median time from diagnosis to treatment with imatinib, mo (range) | 11 (0-158) | 21 (0-120) | 4 (0-166) | 21 (0-163) | .08 |
| Median follow-up after imatinib failure, mo (range) | 28 | 27 | 29 | 32 | .68 |
| Median follow-up after mutation, mo (range) | NA | 26 | 30 | 38 | .64 |
| Median time on imatinib, mo (range) | 27 (2-69) | 25 (2-69) | 21 (1-60) | 37 (2-70) | .22 |
| Characteristic . | Mutation group . | ||||
|---|---|---|---|---|---|
| No mutation . | F317L . | T315I . | Other mutation . | P . | |
| Patients, n | 79 | 20* | 26 | 67 | |
| Age, y (range) | 50 (11-96) | 49 (34-66) | 52 (25-66) | 53 (22-80) | .51 |
| Prior therapy with interferon-α | 41 (52%) | 12 (60%) | 13 (50%) | 45 (67%) | .20 |
| CML stage at the start of imatinib | |||||
| Chronic | 62 (78%) | 12 (60%) | 20 (77%) | 55 (82%) | |
| Accelerated | 12 (15%) | 6 (30%) | 4 (15%) | 10 (15%) | |
| Blastic | 5 (7%) | 2 (10%) | 2 (8%) | 2 (3%) | .53 |
| Best response to imatinib | |||||
| CHR | 33 (41%) | 11 (55%) | 19 (70%) | 31 (46%) | |
| MCyR | 33 (41%) | 7 (35%) | 6 (23%) | 28 (41%) | |
| CCyR | 24 (30%) | 5 (25%) | 5 (19%) | 19 (28%) | .34 |
| Response duration, mo (range) | 25 (2-63) | 23 (2-69) | 20 (1-60) | 35 (2-70) | .048 |
| CML stage at imatinib failure | |||||
| Chronic | 28 (35%) | 8 (40%) | 9 (35%) | 23 (34%) | |
| Accelerated | 29 (37%) | 6 (30%) | 9 (35%) | 34 (51%) | |
| Blastic | 22 (28%) | 6 (30%) | 8 (30%) | 10 (15%) | |
| Myeloid | 15 (68%) | 4 (67%) | 4 (50%) | 6 (60%) | |
| Lymphoid | 7 (32%) | 2 (33%) | 4 (50%) | 4 (40%) | .37 |
| Clonal evolution | 37 (47%) | 8 (40%) | 9 (35%) | 23 (34%) | .19 |
| Transformation to accelerated or blastic phase | 40 (51%) | 6 (30%) | 14 (54%) | 38 (57%) | .20 |
| No. treated with 2nd TKI | 73 | 9 | 14 | 65 | |
| Response to subsequent TKI | |||||
| Hematologic | 61 (84%) | 7 (78%) | 5 (36%) | 53 (82%) | |
| Cytogenetic | 31 (42%) | 3 (33%) | 0 (0%) | 31 (48%) | .003 |
| No. dead | 31 (39%) | 8 (40%) | 11 (42%) | 25 (37%) | .99 |
| Median time from diagnosis to treatment with imatinib, mo (range) | 11 (0-158) | 21 (0-120) | 4 (0-166) | 21 (0-163) | .08 |
| Median follow-up after imatinib failure, mo (range) | 28 | 27 | 29 | 32 | .68 |
| Median follow-up after mutation, mo (range) | NA | 26 | 30 | 38 | .64 |
| Median time on imatinib, mo (range) | 27 (2-69) | 25 (2-69) | 21 (1-60) | 37 (2-70) | .22 |
Data values are numbers followed by percentages in all clinical categories except number of patients, patient age, and time.
CHR indicates complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; and NA, not applicable.
One patient with F317L mutation acquired a T315I mutation and was counted with the group of patients with F317L mutation. Patients with composite mutations including F317L or T315I are included in the groups of F317L and T315I, respectively.